SIRT3 and hepatocellular carcinoma: Intriguingly, HDAC inhibitors appear to inactivate HSCs, sensitize cancer cells to ferroptosis, and enhance the sensitivity of cancer cells to cisplatin therapy, while SIRT3 activators suppress HCC growth [103,156,157].